disitamab vedotin + tislelizumab + oxaliplatin + capecitabine

A combination regimen comprising four agents: **Disitamab vedotin** (an antibody-drug conjugate targeting HER2), **tislelizumab** (a PD-1 immune checkpoint inhibitor), **oxaliplatin** (a platinum-based chemotherapeutic), and **capecitabine** (an oral prodrug of 5-fluorouracil). - Disitamab vedotin consists of a novel humanized anti-HER2 monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a cleavable linker, selectively delivering cytotoxic MMAE to HER2-expressing tumor cells, resulting in cell cycle arrest and apoptosis[2][5][8][10]. - Tislelizumab is a monoclonal antibody that blocks the PD-1 receptor, enhancing T-cell mediated anti-tumor immune responses[3][7]. - Oxaliplatin forms DNA-platinum adducts, disrupting DNA replication and transcription, leading to cancer cell death. - Capecitabine is metabolized to 5-fluorouracil, inhibiting thymidylate synthase and interfering with DNA synthesis. This four-drug combination is under clinical investigation, specifically as first-line therapy for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma[1]. Early data also suggest efficacy in urothelial carcinoma[6][7][9].

Brand names

No unique combination brand name found; components have their own brand names (e.g., Disitamab Vedotin marketed as Aidixi in China)

Other names

Disitamab vedotin + tislelizumab + oxaliplatin + capecitabineDisitamab vedotin combination with CAPOX and tislelizumab